Association of exposure to phthalates with cardiometabolic risk factors in children and adolescents: a systematic review and meta-analysis

2019 ◽  
Vol 26 (35) ◽  
pp. 35670-35686 ◽  
Author(s):  
Mohsen Golestanzadeh ◽  
Roya Riahi ◽  
Roya Kelishadi
2019 ◽  
Vol 22 (15) ◽  
pp. 2823-2834 ◽  
Author(s):  
Elnaz Daneshzad ◽  
Fahimeh Haghighatdoost ◽  
Leila Azadbakht

AbstractObjective:Dietary acid load (DAL) might contribute to change the levels of cardiometabolic risk factors; however, the results are conflicting. The present review was conducted to determine the relationship between DAL and cardiometabolic risk factors.Design:Systematic review and meta-analysis.Setting:A systematic search was conducted in electronic databases including ISI Web of Science, PubMed/MEDLINE, Scopus and Google Scholar for observational studies which assessed cardiometabolic risk factors across DAL. Outcomes were lipid profile, glycaemic factors and anthropometric indices. Effect sizes were derived using a fixed- or random-effect model (DerSimonian–Laird). Also, subgroup analysis was performed to find the probable source of heterogeneity. Egger’s test was performed for finding any publication bias.Results:Thirty-one studies were included in the current review with overall sample size of 92 478. There was a significant relationship between systolic blood pressure (SBP; weighted mean difference (WMD) = 1·74 (95 % CI 0·25, 3·24) mmHg;P= 0·022;I2= 95·3 %), diastolic blood pressure (DBP; WMD = 0·75 (95 % CI 0·07, 1·42) mmHg;P= 0·030;I2= 80·8 %) and DAL in cross-sectional studies. Serum lipids, glycaemic parameters including fasting blood sugar, glycated Hb, serum insulin, homeostatic model assessment of insulin resistance and waist circumference had no significant relationship with DAL. No publication bias was found. BMI was not associated with DAL in both cross-sectional and cohort studies.Conclusions:Higher DAL is associated with increased SBP and DBP. More studies are needed to find any relationship of DAL with lipid profile and glycaemic factors.


2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Asal Ataie-Jafari ◽  
Nazli Namazi ◽  
Shirin Djalalinia ◽  
Pouria Chaghamirzayi ◽  
Mohammad Esmaeili Abdar ◽  
...  

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Zahra Aslani ◽  
Omid Sadeghi ◽  
Motahar Heidari-Beni ◽  
Hoda Zahedi ◽  
Fereshteh Baygi ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


2019 ◽  
Vol 45 (1) ◽  
pp. 35-44 ◽  
Author(s):  
Hsiao‐Huai Kuo ◽  
Kuang‐Te Wang ◽  
Ying‐Hsiang Lee ◽  
Po‐Lin Lin ◽  
Ming‐En Liu ◽  
...  

2016 ◽  
Vol 170 (2-3) ◽  
pp. 290-300 ◽  
Author(s):  
Rebekah Carney ◽  
Jack Cotter ◽  
Tim Bradshaw ◽  
Joseph Firth ◽  
Alison R. Yung

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Motahareh Hasani ◽  
Asieh Mansour ◽  
Hamid Asayesh ◽  
Shirin Djalalinia ◽  
Armita Mahdavi Gorabi ◽  
...  

Abstract Background Evidence exists that glutamine plays multiple roles in glucose metabolism, insulin sensitivity, and anti-inflammatory effects. This systematic review and meta-analysis of controlled trials aimed to assess the effect of glutamine supplementation on cardio-metabolic risk factors and inflammatory markers. Methods The processes of systematic reviews and meta-analyses were performed according to the PRISMA checklist. PubMed, Web of Sciences, Cochrane library, and Scopus databases were search for relevant studies without time or language restrictions up to December 30, 2020. All randomized clinical trials which assessed the effect of glutamine supplementation on “glycemic indices”, “level of triglyceride, “and “inflammatory markers” were included in the study. The effect of glutamine supplementation on cardio-metabolic risk factors and inflammatory markers was assessed using a standardized mean difference (SMD) and 95% confidence interval (CI). Heterogeneity between among studies was assessed using Cochran Q-statistic and I-square. Random/fixed-effects meta-analysis method was used to estimate the pooled SMD. The risk of bias for the included trials was evaluated using the Cochrane quality assessment tool. Results In total, 12 studies that assessed the effect of glutamine supplementation on cardio-metabolic risk factors were included in the study. Meta-analysis showed that glutamine supplementation significantly decreased significantly serum levels of FPG [SMD: − 0.73, 95% CI − 1.35, − 0.11, I2: 84.1%] and CRP [SMD: − 0.58, 95% CI − 0.1, − 0.17, I2: 0%]. The effect of glutamine supplementation on other cardiometabolic risk factors was not statistically significant (P > 0.05). Conclusion Our findings showed that glutamine supplementation might have a positive effect on FPG and CRP; both of which are crucial as cardio-metabolic risk factors. However, supplementation had no significant effect on other cardio-metabolic risk factors.


Sign in / Sign up

Export Citation Format

Share Document